Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

Annals of Hematology

Volumn 88, Issue 4, 2009, Pages 347-350

  Palladini, Giovanni ^a   Russo, Paola ^a   Lavatelli, Francesca ^a   Nuvolone, Mario ^a   Albertini, Riccardo ^a   Bosoni, Tiziana ^a   Perfetti, Vittorio ^a   Obici, Laura ^a   Perlini, Stefano ^a   Moratti, Remigio ^a   Merlini, Giampaolo ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Amyloidosis; Dexamethasone; Melphalan; Response; Thalidomide

Indexed keywords

DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ARTERY EMBOLISM; ARTICLE; BRADYCARDIA; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLUID RETENTION; HEART AMYLOIDOSIS; HEART EJECTION FRACTION; HEART VENTRICLE HYPERTROPHY; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; AMYLOIDOSIS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; HEART DISEASES; HEART FAILURE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; STROKE VOLUME; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 60749115105     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0600-y     Document Type: Article

References (12)

1. Merlini G, Stone MJ (2006) Dangerous small B-cell clones. Blood 108:2520-2530
2. Palladini G, Perfetti V, Obici L et al (2004) Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103:2936-2938
3. Jaccard A, Moreau P, Leblond V et al (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083-1093
4. Wechalekar AD, Goodman HJ, Lachmann HJ et al (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109:457-464
5. Palladini G, Anesi E, Perfetti V et al (2001) A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. Br J Haematol 113:1044-1046
6. Gillmore JD, Goodman HJ, Lachmann HJ et al (2006) Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 107:1227-1229
7. Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 22:3751-3757
8. Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 367:825-831
9. Facon T, Mary JY, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 370:1209-1218
10. Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79:319-328
11. Palladini G, Perfetti V, Perlini S et al (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949-2951
12. Palladini G, Lavatelli F, Russo P et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854-3858